CYP2A7P1: A Drug Target with Implications for Many Diseases (G1550)

Target Name: CYP2A7P1

NCBI ID: G1550

CYP2A7P1

CYP2A7P1: A Drug Target with Implications for Many Diseases

CYP2A7P1, also known as CYP2A18PN, is a gene that encodes for a protein known as CYP2A7P1. This protein is a key regulator of the drug metabolism pathway, and is involved in the metabolism of many drugs, including many statins, antidepressants, and opioids. As a result, CYP2A7P1 has become a drug target of great interest, with researchers studying its role in drug response and drug tolerance.

The CYP2A7P1 gene is located on chromosome 17, and is encoded by the DNA sequence:

```
GATTTACTG CYP2A7P1
```

The protein encoded by this gene is a 16-kDa glycoprotein with a molecular weight of 191.8 kDa. It consists of 115 amino acid residues, and has a calculated pI of 1.18. The protein is expressed in many different tissues and cells, including the liver, heart, and brain.

One of the key functions of CYP2A7P1 is its role in drug metabolism. It is a key regulator of the liver's metabolism of many drugs, including many statins, antidepressants, and opioids. The liver is responsible for metabolizing most drugs that are taken orally, and the CYP2A7P1 gene is involved in this process.

CYP2A7P1 is expressed in the liver, and is primarily expressed in the cytoplasm. It is a good candidate for drug targeting, due to its high level of expression and its location in the liver. Many drugs that are metabolized by the liver are eliminated by the CYP2A7P1 enzyme, and inhibiting this enzyme could be a useful strategy for treating drug-resistant diseases.

In addition to its role in drug metabolism, CYP2A7P1 is also involved in many other processes in the body. It is a key regulator of the production of cell signaling molecules, such as nitric oxide. It is also involved in the production of many other signaling molecules, including cyclic AMP and inositol.

The CYP2A7P1 gene has also been implicated in several diseases, including cardiovascular disease and addiction. Studies have shown that individuals with certain genetic variations in the CYP2A7P1 gene are at increased risk for developing cardiovascular disease, including heart attack and stroke. These genetic variations may also be associated with addiction, as some studies have shown that individuals with certain genetic variations in the CYP2A7P1 gene are more likely to develop addiction.

Despite the many studies that have been conducted on CYP2A7P1, much is still not known about its role in drug metabolism and its potential as a drug target. For example, it is not clear exactly how the CYP2A7P1 enzyme functions, or how it can be inhibited. Additionally, there are many potential drug targets that have been identified in the CYP2A7P1 gene, but it is not clear which one will be the most effective.

In conclusion, CYP2A7P1 is a gene that encodes for a protein that plays a key role in the metabolism of many drugs. Its high level of expression and its location in the liver make it a good candidate for drug targeting. Furthermore, CYP2A7P1 is involved in many other processes in the body, including the production of cell signaling molecules and the regulation of cardiovascular disease and addiction. Further research is needed to fully understand its role in drug metabolism and its potential as a drug target.

Protein Name: Cytochrome P450 Family 2 Subfamily A Member 7 Pseudogene 1

The "CYP2A7P1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CYP2A7P1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets